Petros Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Petros Pharmaceuticals, Inc. (PTPI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.27 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $3.34, a 10.70% decline year-over-year.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $3.74.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.27, a 96.20% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $33.40, a 1.18% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $33.80.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.27 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | $0.99 10-Q · filed 2023-11-15 | ||||||
| 2023-06-30 | $0.99 10-Q · filed 2023-08-14 | ||||||
| 2022-12-31 | $33.40 10-K · filed 2024-04-01 | ||||||
| 2022-09-30 | $3.34 10-Q/A · filed 2022-11-15 | ||||||
| 2022-06-30 | $3.34 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | $3.34 10-Q · filed 2022-05-16 | ||||||
| 2022-01-04 | $33.40 10-K · filed 2024-04-01 | $3.34 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | $33.80 10-K · filed 2023-03-31 | $3.38 10-K · filed 2022-03-31 | |||||
| 2021-09-30 | $3.37 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | $3.37 10-Q · filed 2021-08-16 | ||||||
| 2021-05-11 | $32.10 10-K · filed 2023-03-31 | $3.21 10-Q · filed 2021-08-16 | |||||
| 2021-03-31 | $3.74 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |